陕西医学杂志
陝西醫學雜誌
협서의학잡지
SHAANXI MEDICAL JOURNAL
2013年
12期
1631-1633
,共3页
心肌梗塞/治疗%瑞舒伐他汀%C反应蛋白质
心肌梗塞/治療%瑞舒伐他汀%C反應蛋白質
심기경새/치료%서서벌타정%C반응단백질
Myocardial infarction/therapy%rosu vastatin%C-reactive protein
目的：观察不同剂量瑞舒伐他汀对急性心肌梗死（AMI）患者高敏C-反应蛋白（hs-CRP）的影响。方法：选取40例健康者为正常对照组。40例急性心肌梗死患者为心梗组，并随机分为A组、B组各20例，在给予吸氧、抗凝、扩张冠脉血管等治疗的基础上，A组口服瑞舒伐他汀10mg/d，B组口服瑞舒伐他汀20mg/d，服药4周。比较治疗前心梗组与对照组hs-CRP水平，A组、B组治疗前后hs-CRP、血脂水平，并监测其不良反应。结果：与正常健康人相比较，AMI患者hs-CRP水平明显升高（P＜0．05），治疗4周后，A组、B组hs-CRP、血脂水平均较治疗前明显降低（P均＜0．05），其中B组较A组降低更明显（P＜0．05），且冠脉事件发生率降低（P＜0．05）。结论：AMI患者早期使用较大剂量瑞舒伐他汀（20mg/d）能显著降低患者hs-CRP、血脂水平，减少冠脉事件。
目的：觀察不同劑量瑞舒伐他汀對急性心肌梗死（AMI）患者高敏C-反應蛋白（hs-CRP）的影響。方法：選取40例健康者為正常對照組。40例急性心肌梗死患者為心梗組，併隨機分為A組、B組各20例，在給予吸氧、抗凝、擴張冠脈血管等治療的基礎上，A組口服瑞舒伐他汀10mg/d，B組口服瑞舒伐他汀20mg/d，服藥4週。比較治療前心梗組與對照組hs-CRP水平，A組、B組治療前後hs-CRP、血脂水平，併鑑測其不良反應。結果：與正常健康人相比較，AMI患者hs-CRP水平明顯升高（P＜0．05），治療4週後，A組、B組hs-CRP、血脂水平均較治療前明顯降低（P均＜0．05），其中B組較A組降低更明顯（P＜0．05），且冠脈事件髮生率降低（P＜0．05）。結論：AMI患者早期使用較大劑量瑞舒伐他汀（20mg/d）能顯著降低患者hs-CRP、血脂水平，減少冠脈事件。
목적：관찰불동제량서서벌타정대급성심기경사（AMI）환자고민C-반응단백（hs-CRP）적영향。방법：선취40례건강자위정상대조조。40례급성심기경사환자위심경조，병수궤분위A조、B조각20례，재급여흡양、항응、확장관맥혈관등치료적기출상，A조구복서서벌타정10mg/d，B조구복서서벌타정20mg/d，복약4주。비교치료전심경조여대조조hs-CRP수평，A조、B조치료전후hs-CRP、혈지수평，병감측기불량반응。결과：여정상건강인상비교，AMI환자hs-CRP수평명현승고（P＜0．05），치료4주후，A조、B조hs-CRP、혈지수평균교치료전명현강저（P균＜0．05），기중B조교A조강저경명현（P＜0．05），차관맥사건발생솔강저（P＜0．05）。결론：AMI환자조기사용교대제량서서벌타정（20mg/d）능현저강저환자hs-CRP、혈지수평，감소관맥사건。
Objective:To observe the effects of different doses of Rosuvastatin on high-sensitivity creative protein (hs-CRP) of patients with acute myocardial infarction (AMI) .Methods:Forty healthy people were selected as control group ,and 40 patients with AMI were selected as AMI group .Patients in AMI group were randomly as-signed to 2 groups (A and B) ,with 20 patients in each group .All patients in AMI group were treated with standard treatment including oxygen inhalation ,anticoagulation ,and blood vessel dilatation ,after witch patients in group A were orally administrated with 10mg/d of Rosuvastatin ,and group B received 20mg/d of Rosuvastatin for 4 weeks . hs-CRP levels were compared between control group and AMI group at the baseline .Also ,the baseline levels of hs-CRP and blood lipid in group A and B were compared to those after treatment .Adverse effects were also collected . Results :As compared to control group ,the level of hs-CRP in patients with AMI increased significantly (P<0 . 05) .While after 4-week’s treatment ,the levels of hs-CRP in both group A and B decreased ,as well as blood lipid level (P<0 .05) ,and the decreases were more pronounced in group B than those in group A (P<0 .05) .Incidence of coronary events was also shown decreased (P< 0 .05) .Conclusion:Early use of higher doses of Rosuvastatin (20mg/d) can significantly reduce the levels of hs-CRP and blood lipid ,as well as incidence of coronary events .
